By Associate Professor Megan Amanda Crumbaker

Journal articles

Lin KL; Talmor B; Crumbaker M; Joshua AM, 2025, 'A Review of Hot Flash Management in Patients with Prostate Cancer', Journal of Clinical Endocrinology and Metabolism, 110, pp. 2509 - 2519, http://dx.doi.org/10.1210/clinem/dgaf302

Emmett L; Papa N; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Sandhu S; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ayati N; Niu C; Hofman MS; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 1168 - 1177, http://dx.doi.org/10.1016/S1470-2045(25)00339-0

Shekar S; Hall A; Pham J; Crumbaker M; Liu J; Talmor B; Sim HW; Joshua AM, 2025, 'Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials', Endocrine Oncology, 5, http://dx.doi.org/10.1530/eo-25-0027

Pathmanandavel S; Crumbaker M; Nguyen A; O. Yam A; Wilson P; Niman R; Ayers M; Sharma S; Eu P; J. Martin A; R. Stockler M; M. Joshua A; Emmett L, 2025, 'Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial', Advances in Radiotherapy & Nuclear Medicine, pp. 025110011 - 025110011, http://dx.doi.org/10.36922/arnm025110011

Kostos L; Buteau JP; Kong G; Tran B; Haskali MB; Fahey M; Crumbaker M; Emmett L; Hofman MS; Azad AA, 2025, 'Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 66, pp. 572 - 578, http://dx.doi.org/10.2967/jnumed.124.269252

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Zarba M; O'Sullivan D; El Hajj Chehade R; McKay RR; Pal SK; Beuselinck B; Donskov F; Lalani A-KA; Crumbaker M; Li H; Alva AS; Powles T; Takemura K; Kollmannsberger CK; Wong SS; Wood LA; de Velasco G; Cheung WY; Choueiri TK; Heng DYC, 2025, 'Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).', Journal of Clinical Oncology, 43, pp. 479 - 479, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.479

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura K; Kollmannsberger CK; Crumbaker M; Lalani AKA; Powles T; Ebrahimi H; McKay RR; Lee JL; Kanesvaran R; Choueiri TK; Heng DYC, 2025, 'Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis', European Urology Oncology, 8, pp. 171 - 178, http://dx.doi.org/10.1016/j.euo.2024.12.011

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Lawrence MG; Keerthikumar S; Townley SL; Clark AK; Cuffe GB; Laven-Law G; Hanson AR; Shrestha RK; Knutson TP; Richards MG; Teng L; Choo N; Crumbaker M; Joshua AM; Corey E; Nelson PS; Dehm SM; Risbridger GP; Tilley WD; Hickey TE; Taylor RA; Selth LA, 2025, 'Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants', European Urology Focus, http://dx.doi.org/10.1016/j.euf.2025.03.017

Emmett L; Zheng A; Jin C; Papa N; Khan S; Ayati N; Susman T; Ngai K; Nelson A; Sharma S; Anand R; John N; Crumbaker M; Nguyen A; Herrmann K, 2025, '‘One button push’ fully automated PSMA PET quantification: Correlation with progression free and overall survival in patients undergoing [ ¹⁷⁷ Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer.', Journal of Clinical Oncology, 43, pp. 5054 - 5054, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5054

Emmett L; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Hofman MS; Sandhu S; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ ¹⁷⁷ Lu] Lu-PSMA-617 (ANZUP1901).', Journal of Clinical Oncology, 43, pp. 5011 - 5011, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5011

Sabahi Z; Papa N; Fendler WP; Nguyen A; Wong K; Ayati N; Ho B; Chen J; Cusick T; Burger I; Crumbaker M; Marx GM; Sharma S; Frydenberg M; Sandhu S; Davis ID; Stockler MR; Sweeney C; Joshua AM; Emmett L, 2025, 'Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.', Journal of Clinical Oncology, 43, pp. 5091 - 5091, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5091

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 65, pp. 1939 - 1944, http://dx.doi.org/10.2967/jnumed.124.267606

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura KN; Kollmannsberger CK; Crumbaker M; Lalani A-KA; Powles T; Pal SK; McKay RR; Lee J-L; Kanesvaran R; Choueiri TK; Heng DYC, 2024, 'Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.', Journal of Clinical Oncology, 42, pp. 390 - 390, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.390

Tolmeijer SH; Kwan EM; Ng SWS; Joshua A; Emmett L; Crumbaker M; Hamid AA; Anton A; Horvath LG; Chan J; Bressel M; Buteau JP; Dhiantravan N; Ayati N; Keerthikumar S; Goode D; Hicks R; Hofman MS; Wyatt AW; Sandhu SK, 2024, '1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)', Annals of Oncology, 35, pp. S975 - S976, http://dx.doi.org/10.1016/j.annonc.2024.08.1697

Crumbaker M; Goldstein LD; Murray DH; Tao J; Pathmanandavel S; Boulter N; Ratnayake L; Joshua AM; Kummerfeld S; Emmett L, 2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007

Kumar S; Crumbaker M; Harvey C; Pathmanandavel S; John N; Swiha MM; McDonald MM; Clifton-Bligh R; Lee A; Bastick P; Counter W; Nguyen A; Emmett L, 2023, 'The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy', Journal of Nuclear Medicine, 64, pp. 1412 - 1416, http://dx.doi.org/10.2967/jnumed.123.265759

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; De Abreu Lourenço R; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', Journal of Clinical Oncology, 41, pp. TPS5099 - TPS5099, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5099

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Pemberton L; Allen C; Handel E; Weickhardt AJ; Tran B; Crumbaker M; Shapiro JD; Risbridger GP; Pook DW, 2023, 'Carboplatin in metastatic castrate resistant prostate cancer: A retrospective study of heavily pretreated patients (COMPACT).', Journal of Clinical Oncology, 41, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.158

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', ANNALS OF ONCOLOGY, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; Pasam A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, 'Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', ANNALS OF ONCOLOGY, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Chen S; Petricca J; Ye W; Guan J; Zeng Y; Cheng N; Gong L; Shen SY; Hua JT; Crumbaker M; Fraser M; Liu S; Bratman SV; van der Kwast T; Pugh T; Joshua AM; De Carvalho DD; Chi KN; Awadalla P; Ji G; Feng F; Wyatt AW; He HH, 2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34012-2

Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM, 2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005

Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K, 2022, 'Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series', Asia Pacific Journal of Clinical Oncology, 18, pp. 209 - 216, http://dx.doi.org/10.1111/ajco.13577

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Conduit C; Mak B; Qu W; Lulio JD; Burder R; Bressel M; Cusick T; Dhillon HM; Lourenço RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Allen R; Davis ID; Clark SJ; Horvath LG; Mahon KL, 2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Lau H; Woo H; Bariol S; Gurney H, 2022, 'Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center', Asia Pacific Journal of Clinical Oncology, 18, pp. e23 - e31, http://dx.doi.org/10.1111/ajco.13548

Joshua AM; Gurney H; Dhillon HM; Crumbaker M, 2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005

Nguyen LT; Lo CS; Fyrsta M; Nie J; Yam JY; Yen PH; Le MX; Hersey K; Kenk M; Crumbaker M; Fleshner N; Kulkarni G; Hamilton R; Jewett M; Finelli A; Evans A; Sweet J; Ohashi PS; Joshua AM, 2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, http://dx.doi.org/10.1155/2022/6499344

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', Ebiomedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, http://dx.doi.org/10.21037/tau-20-1444

Bhatnagar A; McKay MJ; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2020, 'Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma', Journal of Mass Spectrometry, 55, http://dx.doi.org/10.1002/jms.4584

Back to profile page